Objectives: Currently pegylated interferon alpha (peg-IFN) and ribavirin treatment is recommended for chronic hepatitis C treatment. The aim of treatment is to provide sustained viral response (SVR).
INTRODUCTION
One of the prominent causes of chronic hepatic disease in the world is Hepatitis C virus (HCV) infection. Throughout the world, approximately 130-210 million people are infected by HCV. 1 HCV can cause a wide range of severe hepatic disease from hepatitis to cirrhosis and hepatocellular carcinoma. 2 There are six genotypes, from 1 to 6, and many subtypes of HCV. 3 Genotype 1 is the most common genotype in the world and subtype 1b is most commonly encountered in Europe. 4 While the genotype 1 responses weakly to treatment, genotype 2 and 3 respond to the treatment better. 5 Pegylated interferon (peg-IFN)-α -ribavirin combination is a reliable and accepted treatment method in chronic Hepatitis C treatment. 6 Currently, two peg-IFNs (α2a and α2b), whose pharmacokinetics is different from each other, are being employed. 7 Recently, phase III studies about peg-IFN-α and ribavirin in combination with protease inhibitors, telaprevir and boceprevir, in genotype 1 patients have been published. 8 The aim of chronic Hepatitis C treatment is to reach sustained viral response (SVR), which is known as undetected serum HCV-RNA levels at 6-months after the treatment is discontinued. It is demonstrated in studies that once SVR is reached, virological relapse possibility is low. Moreover, morbidity and mortality rates due to chronic HCV infection are decreased by antiviral treatment. 5 Some predictors, which have been detected before initiation of treatment, have been reported to be useful in estimating patient SVR beforehand. 6 In this study, we have investigated predictors of treatment response and the treatment response rates, themselves, in 125 chronic hepatitis patients, who have completed the treatment.
MATERIAL AND METHODS
A total of 125 patients, who have applied outpatient clinic of Infectious Diseases and Clinical Microbiology at the School of Medicine in Gaziosmanpasa University between dates June 2006 and June 2011; have been treated for chronic hepatitis C diagnosis and were followed up until 6 months after treatment, were enrolled into the study. Patient data have been recorded retrospectively by medical record review in the files and analyses have been performed according to the obtained results. Predictive markers for treatment response in patients with hepatitis C virus have been investigated. Therefore, age, gender, presence of diabetes mellitus (DM), HCV RNA levels, fibrosis stage in hepatic biopsy, IFN type used, baseline weights before treatment, platelet (PLT) count, baseline lymphocyte count, alanine amino transferase (ALT), hemoglobin (Hb) levels, blood cholesterol level, blood Triglyceride level, albumin level, total bilirubin level, rapid virologic response (RVR) and early virologic response (EVR) have been compared in patients with positive and negative SVRs. Also SVR rates and hematological side effects (neutropenia, anemia, thrombocytopenia) have been compared according to IFN type used in patients.
Treatments in line with national and international guidelines have been initiated and continued. Combination of peg-IFN alpha 2a (180 mg) or 2b (at the dose of 1.5 µg/kg) with adjusted dose of ribavirin according to body weight (1200 mg in patients with body weight >75 kg; 1000 mg/ day in patients with body weight <75 kg) have been given to patients. Majority of patients have received the treatment for 48 weeks. Appropriate dose adjustments have been performed in patients, who developed anemia and cytopenia. Quantitative RNA is studied in patient serums at months 1, 3, 6 and at the end of treatment and 6 months after the treatment has ended. If HCV RNA was negative at the first month of treatment, it was accepted as RVR; if there was more than 2 log decrease compared with baseline values, it was accepted as EVR; and if it was at undetectable levels at 6 months after treatment has ended, it was accepted as SVR. HCV RNA values, which did not decrease more than 2 logs at the third month or which were not negative at the 6th month of treatment were accepted as unresponsive. Unresponsive patients or relapsed patients made up the SVR negative group.
Statistical Analysis
Pearson's chi-square test was used to compare the categorical variables between groups. Categorical variables were presented as count and percentages. Kolmogorov-Smirnov test was used to evaluate whether the distribution of continuous variables were normal. Accordingly, it was seen that all variables displayed a normal distribution. Therefore, two independent sample t test was used to compare the continuous variables 
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RESULTS
A total of 125 patients were enrolled into the study, and 103 patients (82.4%) were female whereas 22 (17.6%) were male; mean of age was 54.74±7.93 years. Of patients 72.8% was in 40-59 year age group. Among 51 patients, whose genotyping was performed, 50 was infected by genotype 1 and only 1 patient had genotype 2 infection.
Of enrolled patients, 18-months follow up data were reached in 121 patients; 78 were positive for SVR (64.4%) and 43 (35.5%) were SVR negative. Predictive markers for SVR in the study were defined as RVR positivity (p<0.001), EVR positivity (p<0.001), baseline high PLT value (240.93 ± 75.61) (p<0.004), baseline total bilirubin level (0.55 ± 0.19) (p<0.001) and high fibrosis stage (according to Knodell or modified ISHAK staging; >2 (p<0.034)) in hepatic biopsy (Table 1) .
In our study, it was investigated if there were predictive markers for RVRs and EVRs (according to gender, age, weight, hepatic fibrosis, HCV RNA level, ALT and PLT counts, Total cholesterol level and IFN types). No predictive parameter was detected for RVR (Table 2 ). Predictive parameters for EVR were defined as absence of DM, high baseline lymphocyte count (2024.74 ± 625.93) and high baseline cholesterol level (EVR positives=180.47 ± 32.77 mg/dl; EVR negatives= 152.00±24.56 mg/dl) ( Table 3) .
While 76 patients received peg-IFNα2b treatment, 45 had peg-IFNα2a treatment; there was no statistical difference in RVR, EVR and SVR between these two groups (Table 4) . And also there was no statistical difference in hematological side effects (neutropenia, anemia, thrombocytopenia) between the two therapy groups (Table 5) .
DISCUSSION
In HCV treatment, HCV RNA negativity (<50 IU/ ml) at the 4th week of treatment is defined as rapid virological response (RVR); decrease >2 log or negativity of HCV RNA at the 12th week of treatment is defined as early virological response (EV), and HCV RNA negativity 6 months after the treatment discontinuation is defined as SVR.
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Predictors for estimation of SVR are investigated in the previous studies, and as a result of these studies two major predictors have been defined for SVR. These are viral genotype and viral load before the treatment. 9 Hadziyannis et al. reported that SVR rates were higher in patients, who were infected by genotypes other than genotype 1 (mainly genotype 2 and 3) and had viral load of <600,000 IU/ml. 10 Zeuzem et al. indicated that treatment responses of genotype 1 infected patients with lower viral loads (<400,000 IU/ml) were higher than those with high viral loads.
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Although the threshold has not been defined absolutely in European Association of Study of the Liver (EASL) guideline, treatment responses of genotype 1 infected patients with viral loads 400,000 -800,000 IU/ml were better. 12 In our study, approximately all of the patients were infected by genotype 1. Therefore, no comparison between genotypes could be performed. Pretreatment viral load was not defined as a significant marker for SVR detection in our patients (p=0.552). It has been thought that this was because of few numbers of patients and they were followed up by different PCR methods during the 5-6years' monitorization period.
It has been reported that RVR was highly predictive for SVR independently from treatment regimens and genotypes. 13 Approximately,15% of HCV genotype 1 infected patients have reached RVR. In retrospective analyses of large scale clinical studies, genotype 1 infected patients, who developed RVR, would develop SVR at a rate of 90%.
13,14 RVR in our patients was 34%. In our study, SVRs in cases with positive RVRs were statistically significantly higher than those in the negative ones (p <0.001). RVR -: ***. RVR +: ***. Data were presented as mean ±standard deviation and count (percentage) Hwang et al. defined predictive markers for RVR in their study as basal mass index, AST⁄ALT rate, ferritin, platelet, LDL, DM and peg-IFN type. 15 In our study, no predictive marker was defined for RVR.
EVR occurs in approximately 80% of HCV genotype 1 infected patient. 13 It has been emphasized in the conducted studies that there was a significant rate of correlation between development of no EVR and unresponsiveness to treatment in genotype 1 infected patients. 16, 17 In our study, EVR rate was 85.8%, and the possibility of SVR positivity in EVR positive patients were significantly higher than the possibility in EVR negative ones (p <0.001). None of patients has developed SVR in EVR negative patients.
Huang CF et al. investigated predictors for EVR in their study and defined two independent risk factors; HCV viral load of < 104 IU/mL after the 4th week of treatment and treatment with high ribavirin dose during the first 12 weeks. 18 In our study, absence of DM, high baseline lymphocyte count (2024.74 ± 625.93) and high baseline cholesterol levels (in EVR positive patients= 180.47 ± 32.77 mg/dl and in the negatives= 152.00 ± 24.56) were defined as the predictive parameters for EVR.
While SVR would not develop in patients without EVR, treatment is suggested to be stopped, it is suggested that the treatment is elongated for 48 weeks in genotype 1 infected patients with EVR development. 17 It has been reported that if HCV RNA negativity is developed between 4-12 weeks in genotype 1 infected patient, then SVR rate would be around at 66%, whereas if it is developed between 12-24 weeks, the SVR rate would be around 45%. The statement of "slow responder(s)" is used for patients, whose HCV RNA becomes negative at the 12-24 weeks of treatment, and treatment elongation to 72 weeks is reported to decrease the relapse rate in these patients at a great extend. 19, 20 In a similar studies, pegylated interferon dose (1.5 µg/kg/week, sequentially 0.5 µg/kg/week), ribavirin dose (>10.6 mg/kg), female gender, non-African American ethnic background, high ALT (3 folds higher than the upper normal limit), low body weight (<75 kg), absence of insulin resistance, absence of bridging fibrosis and cirrhosis in hepatic biopsy were reported to be positive predictors for SVR. 6 In this present study, predictive markers for SVR were defined as RVR positivity (p<0.001), EVR positivity (p<0.001), high baseline PLT value (p<0.038), high baseline total bilirubin level (p<0.001) and low fibrosis stage in hepatic biopsy (≤ 2) (p<0.034). Few numbers of cases in our study has been evaluated as a limitation. In some of the recent studies, it has been reported that peg-IFNα2a use in the treatment has increased SVR rate more significantly than peg-IFNα2b use. 21, 22 According to IDEAL study, there was no significant difference on SVR rate between the two peg-IFN molecules. 7 In our study, although there were few patients receiving peg-IFNα2a, there was no statistically significant difference in SVR development rate between the two patient groups.
In recent publications, IL28B gene region polymorphism is underlined as the strongest pretreatment predictor in viral response, relapse and SVR rates in HCV. 23 In the conducted studies it is reported that SVR rates in genotype 1 and 4 infected patients have been detected as 40-60% after 48-week treatment. In line with the mentioned results, SVR rate of our patients was 64.4%.
Peg-IFN/ribavirin combination can cause some negative effects in HCV treatment. The most important ones among these negative effects are flu-like symptoms, psychiatric disorders, autoimmune reactions and hematological toxicities. These negative effects can be successfully managed in many patients; peg-IFN or ribavirin dose should be decreased or stopped temporarily in approximately 20-40% of cases. Moreover, drug treatment should be totally withdrawn in 10-14% of patients due to sere side effects. 9, 17 In a meta-analysis, which has compared side effects that would prevent continuation of the treatment between two peg-IFN groups, it has been reported that there was no difference between the groups. 24 In line with these studies, there was no statistical difference in hematological side effects between two peg-IFN groups in our study.
Conclusion
It is getting more important to demonstrate the efficacy of anti-HCV treatment and to comprehend predictive markers for the treatment response. As SVR rates differ among patients according to genotypes, the rates differ due to other significant SVR predictors. SVR rates in patients are affected by other factors including RVR and EVR. Therefore, it is obvious that these factors should be considered to a great extend in the treatment plans.
